ATE195429T1 - Neue zusammensetzungen, die sertralin und einem 5-ht1d-rezeptoragonisten oder antagonisten enthalten - Google Patents
Neue zusammensetzungen, die sertralin und einem 5-ht1d-rezeptoragonisten oder antagonisten enthaltenInfo
- Publication number
- ATE195429T1 ATE195429T1 AT95306249T AT95306249T ATE195429T1 AT E195429 T1 ATE195429 T1 AT E195429T1 AT 95306249 T AT95306249 T AT 95306249T AT 95306249 T AT95306249 T AT 95306249T AT E195429 T1 ATE195429 T1 AT E195429T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- disorder
- disease
- antagonist
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/306,230 US5597826A (en) | 1994-09-14 | 1994-09-14 | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE195429T1 true ATE195429T1 (de) | 2000-09-15 |
Family
ID=23184390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95306249T ATE195429T1 (de) | 1994-09-14 | 1995-09-07 | Neue zusammensetzungen, die sertralin und einem 5-ht1d-rezeptoragonisten oder antagonisten enthalten |
Country Status (10)
Country | Link |
---|---|
US (1) | US5597826A (de) |
EP (1) | EP0701819B1 (de) |
JP (1) | JPH08109130A (de) |
AT (1) | ATE195429T1 (de) |
CA (1) | CA2158108C (de) |
DE (1) | DE69518373T2 (de) |
DK (1) | DK0701819T3 (de) |
ES (1) | ES2148445T3 (de) |
GR (1) | GR3034353T3 (de) |
PT (1) | PT701819E (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6992188B1 (en) | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
CA2290966C (en) | 1997-07-01 | 2005-12-20 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
SK179899A3 (en) | 1997-07-03 | 2001-12-03 | Du Pont Pharm Co | Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
US6228864B1 (en) * | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
US6037360A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Incorporated | Administration of 5-HT3 receptor antagonists to treat premature ejaculation |
US6168805B1 (en) | 1998-05-07 | 2001-01-02 | Endo Pharmaceuticals, Inc. | Aqueous process for manufacturing paroxetine solid dispersions |
US6365589B1 (en) | 1998-07-02 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists |
US6124463A (en) * | 1998-07-02 | 2000-09-26 | Dupont Pharmaceuticals | Benzimidazoles as corticotropin release factor antagonists |
US6579899B1 (en) | 1998-07-16 | 2003-06-17 | Massachusetts Institute Of Technology | Composition for treatment of stress |
CA2337507A1 (en) * | 1998-07-16 | 2000-01-27 | Massachusetts Institute Of Technology | Composition for treatment of stress |
US6197798B1 (en) | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
PL348119A1 (en) * | 1998-10-13 | 2002-05-06 | Pfizer Prod Inc | Sertraline oral concentrate |
US6727283B2 (en) * | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
IL132500A0 (en) | 1998-10-29 | 2001-03-19 | Pfizer Prod Inc | Stereoselective microbial reduction of a racemic tetralone |
US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
KR100719977B1 (ko) | 1999-09-03 | 2007-05-21 | 에이피비아이 홀딩스, 엘엘씨 | 성기능 장애 치료를 위하여 효과 발현이 신속한 선택적 세로토닌 재흡수 억제제를 사용하는 방법 |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
DE60110896T2 (de) * | 2000-01-18 | 2006-01-12 | Novartis Ag | Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion |
GB2362826A (en) * | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
MXPA03011083A (es) | 2001-06-11 | 2004-07-08 | Biovitrum Ab | Compuestos de sulfonamida sustituida, procedimiento para su preparacion, y su uso como medicamento para el tratamiento de trastornos del sistema nervioso central. obesidad y diabetes tipo ii. |
WO2003007887A2 (en) | 2001-07-20 | 2003-01-30 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7943639B2 (en) | 2002-06-20 | 2011-05-17 | Proximagen Limited | Compounds |
EP1897876A3 (de) | 2002-06-20 | 2009-03-18 | Biovitrum AB (publ) | Zur Behandlung von Obesitas, Typ II-Diabetes und ZNS-Erkrankungen geeignete Verbindungen |
NZ552283A (en) * | 2002-06-20 | 2008-07-31 | Biovitrum Ab Publ | New compounds useful for the treatment of obesity, type II diabetes and CNS disorders |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
US20050070577A1 (en) * | 2003-07-03 | 2005-03-31 | Pfizer Inc. | Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist |
AR047553A1 (es) | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
WO2005051488A1 (en) * | 2003-11-26 | 2005-06-09 | Pfizer Products Inc. | Combination of dopamine agonists and monoamine reuptake inhibitors |
SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Biovitrum Ab | Benzofuranes |
EP1725236A4 (de) * | 2004-03-11 | 2009-05-13 | Glaxo Group Ltd | Neue m3 muscarinische acetylcholin-rezeptor-antagonisten |
EP1809614B1 (de) * | 2004-04-08 | 2014-05-07 | TargeGen, Inc. | Benzotriazin-kinasehemmer |
AU2005249372A1 (en) * | 2004-05-06 | 2005-12-15 | Cydex Pharmaceuticals, Inc. | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
WO2006024034A1 (en) | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
AU2006227628A1 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
MX2007008848A (es) * | 2005-06-08 | 2008-04-16 | Targegen Inc | Metodos y composiciones para el tratamiento de desordenes oculares. |
US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
CN101273024A (zh) * | 2005-07-29 | 2008-09-24 | 康瑟特制药公司 | 新颖苯并[d][1,3]-二氧杂环戊烯衍生物 |
US20070049626A1 (en) * | 2005-08-26 | 2007-03-01 | Tran Pierre V | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
US20070112031A1 (en) * | 2005-11-14 | 2007-05-17 | Gant Thomas G | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
BR122021011788B1 (pt) | 2005-11-01 | 2022-01-25 | Impact Biomedicines, Inc | Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007056075A2 (en) * | 2005-11-02 | 2007-05-18 | Targegen, Inc. | Six membered heteroaromatic inhibitors targeting resistant kinase mutations |
US7893053B2 (en) * | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
BRPI0720252A2 (pt) * | 2006-12-08 | 2014-01-07 | Xenoport Inc | Uso de pró-fármacos de análogos de gaba para tratar doenças |
GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
EP2727915B1 (de) * | 2007-09-13 | 2016-04-13 | Concert Pharmaceuticals Inc. | Synthese von deuterierten Catecholen und Benzo[D][1,3]dioxolen und Derivate davon |
EP2273880B1 (de) | 2008-04-28 | 2014-12-31 | Zogenix, Inc. | Neuartige formulierungen zur behandlung von migräne |
CN102395359A (zh) * | 2009-03-16 | 2012-03-28 | Ipintl有限责任公司 | 治疗阿尔茨海默病和骨质疏松症以及减缓衰老 |
BR112012000254A2 (pt) | 2009-07-08 | 2016-02-16 | Dermira Canada Inc | análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas. |
KR101875238B1 (ko) * | 2010-06-24 | 2018-07-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 포스포디에스테라아제 (pdes) 저해제로서의 융합 헤테로시클릭 화합물 |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
TWI570122B (zh) * | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
TW201341367A (zh) | 2012-03-16 | 2013-10-16 | Axikin Pharmaceuticals Inc | 3,5-二胺基吡唑激酶抑制劑 |
JP6006009B2 (ja) * | 2012-06-14 | 2016-10-12 | ユー・ディー・シー アイルランド リミテッド | 化合物、有機電界発光素子、有機電界発光素子用材料並びに該有機電界発光素子を用いた発光装置、表示装置及び照明装置 |
EP3610890A1 (de) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Verfahren und zusammensetzungen zur behandlung von schizophrenie |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
CN107250116B (zh) | 2014-12-23 | 2020-10-27 | 艾士盟医疗公司 | 3,5-二氨基吡唑激酶抑制剂 |
WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
EP3970710A4 (de) * | 2019-05-13 | 2023-06-14 | VASTHERA Co. Ltd. | Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von degenerativen hirnerkrankungen durch autophagieaktivierung |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4029731A (en) | 1974-11-06 | 1977-06-14 | Pfizer Inc. | Aminophenyltetralin compounds |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4839104A (en) | 1987-06-11 | 1989-06-13 | Pfizer, Inc. | Process for preparing sertraline intermediates |
US4772288A (en) | 1987-06-15 | 1988-09-20 | Borner William H | Method for producing implantable ligament and tendon prostheses and prostheses produced thereby |
US4855500A (en) | 1988-05-04 | 1989-08-08 | Pfizer Inc. | Process for preparing a ketimine |
US4897405A (en) | 1989-04-21 | 1990-01-30 | American Home Products Corporation | Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5130338A (en) * | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
US4940731A (en) * | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
US5082970A (en) | 1991-03-06 | 1992-01-21 | Pfizer Inc. | Process for recycling amine isomer |
DE69232003T2 (de) * | 1991-09-18 | 2002-04-25 | Glaxo Group Ltd | Benzanilidderivate als 5-HT1D-Antagonisten |
US5196607A (en) | 1992-02-14 | 1993-03-23 | Pfizer Inc. | Process for preparing ketone enantiomer |
US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
JP2810236B2 (ja) * | 1993-03-16 | 1998-10-15 | フアイザー・インコーポレイテツド | ナフタレン誘導体 |
MX9700693A (es) * | 1994-07-26 | 1997-04-30 | Pfizer | Derivados del 4-indol. |
-
1994
- 1994-09-14 US US08/306,230 patent/US5597826A/en not_active Expired - Fee Related
-
1995
- 1995-09-07 DE DE69518373T patent/DE69518373T2/de not_active Expired - Fee Related
- 1995-09-07 PT PT95306249T patent/PT701819E/pt unknown
- 1995-09-07 AT AT95306249T patent/ATE195429T1/de not_active IP Right Cessation
- 1995-09-07 EP EP95306249A patent/EP0701819B1/de not_active Expired - Lifetime
- 1995-09-07 DK DK95306249T patent/DK0701819T3/da active
- 1995-09-07 ES ES95306249T patent/ES2148445T3/es not_active Expired - Lifetime
- 1995-09-12 CA CA002158108A patent/CA2158108C/en not_active Expired - Fee Related
- 1995-09-14 JP JP7236951A patent/JPH08109130A/ja active Pending
-
2000
- 2000-09-06 GR GR20000402041T patent/GR3034353T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2158108C (en) | 1999-03-16 |
EP0701819A3 (de) | 1999-06-23 |
JPH08109130A (ja) | 1996-04-30 |
CA2158108A1 (en) | 1996-03-15 |
EP0701819A2 (de) | 1996-03-20 |
EP0701819B1 (de) | 2000-08-16 |
ES2148445T3 (es) | 2000-10-16 |
DK0701819T3 (da) | 2000-10-16 |
PT701819E (pt) | 2000-12-29 |
US5597826A (en) | 1997-01-28 |
GR3034353T3 (en) | 2000-12-29 |
DE69518373T2 (de) | 2000-12-21 |
DE69518373D1 (de) | 2000-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE195429T1 (de) | Neue zusammensetzungen, die sertralin und einem 5-ht1d-rezeptoragonisten oder antagonisten enthalten | |
ATE399005T1 (de) | Pharmazeutische zusammensetzung aus einem beta-3- adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor und deren verwendung zur behandlung von blasenfunktionsstoerungen | |
DE602005027714D1 (de) | Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität | |
DK0885220T3 (da) | Tropanderivater, deres fresmtilling og anvendelse | |
WO2007081542A3 (en) | Tetralone-based monoamine reuptake inhibitors | |
PT1267869E (pt) | Antogonistas de receptor de glutamato metabotropico para o tratamento de tolerancia e de dependencia | |
RU2004112546A (ru) | Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина | |
UY26924A1 (es) | Derivados de fenoxibencilamina como ssri | |
NO20055206L (no) | 4-(2-fenyloksyfenyl)-piperidin eller -1,2,3,6-tetrahydropyridinderivater som serotonin-reopptaksinhibitorer | |
DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
BR0209343A (pt) | Antidepressivos de azaheterociclilmetila derivados de [1,4]-benzodioxanos oxaheterociclo-fundidos; métodos de tratamento usando tais compostos; processo para prepará-los | |
CA2490638A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
WO2004100939B1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
NO20063267L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en histamin 3-reseptorantagonist, invers agonist eller partiell agonist | |
RU2006140687A (ru) | Новые алкил-замещенные производные пиперазина и их применение в качестве ингибиторов обратного захвата моноаминовых нейротрансмиттеров | |
UA84692C2 (ru) | Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения | |
JP2006507363A5 (de) | ||
BR0314431A (pt) | Derivados de piperidina antidepressiva dos benzodioxanos fundidos por heterocilo | |
BRPI0412268A (pt) | compostos contendo um inibidor seletivo da recaptação de serotonina e antagonista de receptor 5-ht2a | |
MXPA05004192A (es) | Tetralinas e indanos sustituidos. | |
DK1687288T3 (da) | Substituerede arylcycloalkanoderivater og fremgangsmåder til anvendelse deraf | |
PT1282414E (pt) | Compostos derivados de felbamato para o tratamento da dor neuropatica | |
ATE396996T1 (de) | Selektive d1/d5 rezeptorantagonisten zur behandlung von fettleibigkeit und von zns störungen | |
BR0313524A (pt) | Compostos de diarila como inibidores de recaptação de mono-amina | |
WO2022036140A3 (en) | Klf11 sirna for treatment of diabetes and obesity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |